Maternal GNAS Contributes to the Extra-Large G Protein \( \alpha \)-Subunit (XL\( \alpha \)) Expression in a Cell Type-Specific Manner

Qiuxia Cui\(^1,2\), Cagri Aksu\(^1\), Birol Ay\(^1\), Claire E. Remillard\(^1\), Antonius Plagge\(^3\), Mina Gardezi\(^1\), Margaret Dunlap\(^4\), Louis C. Gerstenfeld\(^4\), Qing He\(^1,5\) and Murat Bastepe\(^1\)*

1 Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States, 2 Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China, 3 Department of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom, 4 Department of Orthopaedic Surgery, Boston University School of Medicine, Boston, MA, United States, 5 School of Stomatology, Wuhan University, Wuhan, China

GNAS encodes the stimulatory G protein alpha-subunit (Gs\( \alpha \)) and its large variant XL\( \alpha \). Studies have suggested that XL\( \alpha \) is expressed exclusively paternally. Thus, XL\( \alpha \) deficiency is considered to be responsible for certain findings in patients with paternal GNAS mutations, such as pseudo-pseudohypoparathyroidism, and the phenotypes associated with maternal uniparental disomy of chromosome 20, which comprises GNAS. However, a study of bone marrow stromal cells (BMSC) suggested that XL\( \alpha \) could be biallelically expressed. Aberrant BMSC differentiation due to constitutively activating GNAS mutations affecting both Gs\( \alpha \) and XL\( \alpha \) is the underlying pathology in fibrous dysplasia of bone. To investigate allelic XL\( \alpha \) expression, we employed next-generation sequencing and a polymorphism common to XL\( \alpha \) and Gs\( \alpha \), as well as A/B, another paternally expressed GNAS transcript. In mouse BMSCs, Gs\( \alpha \) transcripts were 48.4 ± 0.3% paternal, while A/B was 99.8 ± 0.2% paternal. In contrast, XL\( \alpha \) expression varied among different samples, paternal contribution ranging from 43.0 to 99.9%. Sample-to-sample variation in paternal XL\( \alpha \) expression was also detected in bone (83.7–99.6%) and cerebellum (83.8 to 100%) but not in cultured calvarial osteoblasts (99.1 ± 0.1%). Osteoblastic differentiation of BMSCs shifted the paternal XL\( \alpha \) expression from 83.9 ± 1.5% at baseline to 97.2 ± 1.1%. In two human BMSC samples grown under osteoinductive conditions, XL\( \alpha \) expression was also predominantly monoallelic (91.3 or 99.6%). Osteoblastic differentiation of BMSCs shifted the paternal XL\( \alpha \) expression from 83.9 ± 1.5% at baseline to 97.2 ± 1.1%. In two human BMSC samples grown under osteoinductive conditions, XL\( \alpha \) expression was also predominantly monoallelic (91.3 or 99.6%). Osteoblastic differentiation of BMSCs shifted the paternal XL\( \alpha \) expression from 83.9 ± 1.5% at baseline to 97.2 ± 1.1%. In two human BMSC samples grown under osteoinductive conditions, XL\( \alpha \) expression was also predominantly monoallelic (91.3 or 99.6%). Osteoblastic differentiation of BMSCs shifted the paternal XL\( \alpha \) expression from 83.9 ± 1.5% at baseline to 97.2 ± 1.1%. In two human BMSC samples grown under osteoinductive conditions, XL\( \alpha \) expression was also predominantly monoallelic (91.3 or 99.6%). Osteoblastic differentiation of BMSCs shifted the paternal XL\( \alpha \) expression from 83.9 ± 1.5% at baseline to 97.2 ± 1.1%

Keywords: GNAS, stimulatory G protein, imprinting, osteoblasts, bone marrow stromal cells, fibrous dysplasia of bone
INTRODUCTION

GNAS is an imprinted gene encoding the alpha-subunit of the stimulatory G protein (Gsa), a signaling protein mediating the actions of many endogenous molecules via generation of cAMP (Plagge et al., 2008; Weinstein et al., 2004; Mantovani et al., 2016). Loss-of-function mutations or epigenetic alterations of GNAS are responsible for different human diseases that involve abnormal skeletal development, metabolism, and hormone actions, such as pseudohypoparathyroidism 1a (MIM: 103580). Gain-of-function GNAS mutations affecting the activity of Gsa are found in a variety of benign and malignant tumors, as well as in patients with fibrous dysplasia of bone and McCune-Albright syndrome (MIM: 174800). GNAS gives rise to multiple additional products showing exclusively maternal or paternal expression (Bastepe, 2007; Kelsey, 2010). The extra-large G-alpha subunit (XLα) is a variant of Gsa that uses a separate promoter and a unique first exon that splices onto Gsa exon 2 (Kehlenbach et al., 1994; Hayward et al., 1998). Hence, XLα is partly identical to Gsa and can mimic the latter regarding cAMP generation (Klemke et al., 2000; Bastepe et al., 2002); however, XLα mediates additional cellular actions, such as stimulation of IP3/PKC signaling and inhibition of clathrin-mediated endocytosis (He et al., 2015; He et al., 2017; He et al., 2019).

XLα expression has been shown to occur exclusively from the paternal allele (Hayward et al., 1998), unlike Gsa, which is biallelic in most tissues. Thus, a GNAS mutation is predicted to affect XLα only if it resides on the paternal allele. For example, the GNAS mutations causing pseudohypoparathyroidism type-1a are inherited maternally (Davies and Hughes, 1993) and, therefore, disrupt one copy of Gsa without affecting XLα. In contrast, the same mutations in patients with pseudo-pseudohypoparathyroidism and thus disrupt both XLα and one copy of Gsa. The severe intrauterine growth retardation observed in pseudo-pseudohypoparathyroidism is attributed to XLα deficiency (Richard et al., 2013). In addition, recent studies have described patients with maternal uniparental disomy of chromosome 20 (matUPD20, MIM: 617352)—the genomic region comprising GNAS—who display Silver-Russell syndrome-like features including perinatal growth retardation and intractable feeding difficulties (Mulchandani et al., 2016; Kawashima et al., 2018). The phenotypes associated with matUPD20 are similar to those observed in children with large paternal GNAS deletions (Aldred et al., 2002; Genevieve et al., 2005) and thus attributed largely to XLα deficiency. Moreover, a recent study described an adult patient with hypophosphatemia and osteopetrosis who carried a nonsense mutation within the first XLα exon (Chen et al., 2020). This defect was also paternally inherited, consistent with the evidence that XLα is expressed from the paternal allele. Nevertheless, a study demonstrated XLα expression from both alleles in human bone marrow stromal cells (BMSCs) from normal and fibrous dysplastic tissues (Michienzi et al., 2007). The analyzed BMSCs were clonogenic, and interestingly, Gsa expression was also shown to be allelically, but randomly, skewed, suggesting that the observed alterations in allelic XLα and Gsa expression may have been secondary to the cloning.

BMSCs include mesenchymal progenitor/stem cells capable of differentiating into multiple different lineages. Gsa signaling promotes the commitment of mesenchymal progenitors into the osteoblast lineage while restricting osteoblast differentiation (Wu et al., 2011). Accordingly, a gain-of-function GNAS mutation results in the aberrant differentiation of BMSCs into osteoblasts, the primary cellular mechanism underlying fibrous dysplasia of bone (Xiao et al., 2019). The causative GNAS mutations are heterozygous and located in exons shared by Gsa and XLα (Weinstein et al., 1991; Schwindinger et al., 1992). It has been shown that these mutations increase the baseline activity of not only Gsa but also XLα (Klemke et al., 2000; He et al., 2015). Thus, whether XLα is expressed monoallelically or biallelically in BMSCs could have strong implications for fibrous dysplasia pathogenesis. Moreover, as mentioned above, the phenotypes attributed to the loss of XLα in vivo are based on the notion that XLα is expressed in an exclusively paternal manner. If, however, tissue-specific biallelic XLα expression exists, then our understanding of its physiological roles and its involvement in GNAS-related diseases may have to be revised.

In this study, we investigated the allele-specific expression of XLα in non-clonal mouse and human BMSCs and other cells and tissues. We quantitated allelic contribution by employing next-generation sequencing (NGS) of RT-PCR amplicons carrying a polymorphism. Our results revealed a significant contribution from the maternal GNAS allele in non-differentiated BMSCs but not in osteogenically differentiated BMSCs or calvarial osteoblasts.

MATERIALS AND METHODS

Mice
XLα knockout (XLKO) mice, carrying a disruption in the first exon of XLα, have been described (Plagge et al., 2004) and maintained in the CD1 background. Wildtype 129/Sv and C57BL/6 mice (Jackson Laboratory) were mated to obtain F1 generation hybrid offspring. Both male and female mice were analyzed. All mice experiments were conducted according to the accepted standards of the Institutional Animal Care and Use Committee and approved by the Massachusetts General Hospital Subcommittee on Research Animal Care.

Restriction Digestion for Confirming Maternal and Paternal XLKO Samples and Determining the Parental Contribution of Gnas Transcripts
The methylation-sensitive restriction enzyme HpaII (New England Biolabs) was used to digest the genomic DNA (1 µg) from tails of offspring derived from matings between heterozygous XLKO mice. Digested DNA was purified using the QIAquick PCR purification kit (Qiagen) and eluted with 30 µl water. Then, 2 µl of each sample was used as a template for genotyping PCR, as described (Plagge et al., 2004). To determine the parental contribution of Gsa, XLα, and A/B transcripts,
RT-PCR products from tissues of mice heterozygous for the C-to-G SNP in exon 11 (rs13460569) were incubated (37°C, 6 h) with BanII (New England BioLabs) and analyzed by agarose gel electrophoresis, as described (Tafaj et al., 2017).

Mouse Primary Cell Cultures and Osteogenic Differentiation

Mouse BMSCs were harvested by flushing the marrow out of long bones (femurs and tibias) of 14 week-old mice, as described (Wu et al., 2011). Cells were plated at a density of 0.5 × 10^6 cells/cm^2 and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, United States) containing 10% Fetal Bovine Serum (FBS) (HyClone, United States). Non-adherent cells were washed off, and the adherent cells were cultured for 1 week, followed by RNA extraction. Primary calvarial pre-osteoblasts were isolated at postnatal day five by serial collagenase digestion, as described (Mariot et al., 2011). Cells were seeded at a density of 10,000 cells/well in 12-well plates and cultured in Modified Eagle’s Medium (MEM) (Gibco, United States) containing 10% FBS. Osteoblastic differentiation was induced by adding ascorbic acid (> 50 µg/ml) and β-glycerol phosphate (10 mM) (Sigma-Aldrich), as described (Wu et al., 2011). Differentiation medium for BMSCs also included 10 nM dexamethasone (Sigma-Aldrich).

Human BMSCs

Cells were obtained from participants who underwent total hip arthroplasty surgery at Boston Medical Center between 2019 and 2020. All human research was done under a Boston University School of Medicine Institutional Research Board Approved protocol: “Bone Tissues Repository,” IRB Number: H-35199, with patients’ consents per current HIPAA regulations prior to surgery and specimen collection. The femoral head and reamings, from the coring of the acetabulum, were collected during total hip arthroplasty. After multiple washes using DPBS (HyClone Laboratories) containing an antibiotic-antimycotic mixture (Thermo Fischer Scientific) cells were suspended in DPBS. 24 million cells/well were seeded in each well of 6-well plates (Corning Inc.), treated with Animal Component-Free Cell Attachment Substrate (Stem Cell Technologies) diluted 1:150 in DPBS. Cells were cultured in an incubator at 37°C, 5% CO2, and > 90% humidity. A half media change was performed on day 4 and a full media change on day six after plating. Cells were then grown in basal medium supplemented with osteoinductive factors (Stem Cell Technologies) for 21 days. Differentiation medium for BMSCs also included 10 nM dexamethasone (Sigma-Aldrich).

Total RNA Extraction, RT-PCR and qRT-PCR Amplification

Total RNA of mouse organs was extracted by using Trizol® Reagent (Life Technologies) followed by the Qiagen RNeasy® Plus Mini Kit. Total RNA of human BMS Cs was extracted using 4 M Guanidine-HCl, 1% Triton X-100, 10 mM Tris HCl, 2 mM EDTA (pH 7.4). cDNA was synthesized using the New England Biolabs PreCipitation II First-strand cDNA synthesis kit.

Total RNA of calvarial osteoblasts and BMSC were isolated by using the Qiagen RNEasy® Plus Mini kit. One µg total RNA was reverse transcribed using the Superscript III First-Strand Synthesis System (Invitrogen) and then subjected to PCR using the PCR Master Mix (Promega). PCR mixture contained 2 µL cDNA in a final volume of 20µL. PCR included 1 cycle at 94°C for 5 min, followed by 40 cycles of 94°C for 30 s, 56°C for 30 s and 72°C for 2 min, and a final extension at 72°C for 7 min. For XLas and A/B, nested PCR was performed using, as template, the primary PCR product diluted 1:10 or 1:2, respectively. qRT-PCR included 1 cycle at 50°C for 2 min and 94°C for 15 min, followed by 50 cycles of 94°C for 15 s, 60°C for 20 s, and 72°C for 20 s. The PCR primers are listed in Supplementary Table 1.

Sequence Analysis of RT-PCR Products

The RT-PCR products were purified by the QIAquick PCR Purification kit. Both Sanger sequencing and NGS was performed at the Massachusetts General Hospital DNA Core. Primers for Sanger sequencing were the same as PCR primers. For NGS, purified PCR products were first fragmented and then subjected to NGS library preparation, followed by sequencing on the Illumina MiSeq. The reads were analyzed following automated de novo sequence assembly. The authenticity of the amplicons was confirmed by the unique first exon sequences of XLas and A/B. To determine the relative contributions of the parental alleles, the ratio of reads containing one of the nucleotides to the total number of reads at rs13460569 (mouse) or rs7121 (human) was calculated for each sample.

Genomic DNA Methylation Analysis

Genomic DNA (600 ng) from non-differentiated and differentiated BMSCs (the same samples as those used for allelic XLas expression) was treated with sodium bisulfite by using the EZ DNA Methylation gold kit (Zymo Research), and the converted DNA was recovered in 10 µl. Primary PCR was performed using 2 µl bisulfite-treated DNA as template in a total reaction volume of 40 µl. The nested PCR used 2 µl of the primary PCR product. PCR included initial denaturation at 95°C for 5 min, 35 cycles of 95°C for 30 s, 56°C for 30 s, 72°C for 30 s, and final extension at 72°C for 10 min. Primers for the region within XLas exon were previously described (Liu et al., 2000). Primers for the XLas promoter were as follows: 5′-GATGGGGAGGGAGTTTTTA-3′ (forward) and 5′-AAAACTAAAAACAAAAACCATAACT-3′ (reverse). Nested PCR used the same forward primer together with the following reverse primer: 5′-TCACCTTCTAATTACACTTACCC-3′. The amplicons were subjected to NGS at the Massachusetts General Hospital DNA Core. To calculate the degree of methylation, paired-end NGS reads were aligned using the BWA-MEM algorithm to a reference reflecting bisulfite-induced alterations except for the CpG dinucleotides. The FreeBayes variant detector was then used to identify each C-to-T variant and the allelic balance (i.e., C is methylated and T non-methylated). BWA-MEM and FreeBayes were run on the Galaxy platform1 (Afgan et al., 2018).

1https://usegalaxy.org/
Statistical Analyses
Outliers were identified by the Grubbs test and excluded. One-way ANOVA followed by Tukey’s post-hoc test was used to analyze the differences among three or more groups. The student’s t-test (two-tailed) was used between two groups. The paired Student’s t-test (two-tailed) was employed for the differences between non-differentiated and differentiated BMSC samples. Wilcoxon rank-sum test was performed to compare the groups regarding the distribution of the data. One-sample t-test was performed to determine the significance of the difference between the maternal expression in non-differentiated BMSCs and the hypothetical value of 0%. P < 0.05 were considered significant. Analyses were performed using Prism 8 (GraphPad).

RESULTS
Comparing XLαs mRNA Levels in Wildtype and XLKO Mice to Determine Allele-Specific XLαs Expression
To examine the allelic expression profile of XLαs in bone, we first employed adult XLKO mice, because disruption of paternal XLαs first exon in those mice was reported to cause a dramatic reduction of XLαs transcript levels in various tissues (Plagge et al., 2004). The maternal, paternal, and homozygous XLKO mice were derived from matings between heterozygous XLKO mice. The previously described genotyping approach for these mice (Plagge et al., 2004) is unable to distinguish maternal from paternal XLKO mice. We thus performed genotyping before and after digestion of genomic DNA with the methylation-sensitive restriction enzyme HpaII, which cleaves the unmethylated, paternal allele at multiple sites and, thereby, prevents it from serving as a template in PCR (Figure 1A). The PCR performed following the HpaII digest detected only the intact maternal allele and allowed us to identify the parental origin of the targeted allele. In the absence of the HpaII digestion, heterozygotes showed a double band, the upper one representing the targeted allele, and wildtype (WT) and homozygous XLKO mice yielded only the smaller or the larger product, respectively (Figure 1B). Following the HpaII digest, only the smaller PCR product was detected in WT and paternal XLKO mice, and only the larger PCR product was observed in homozygous and maternal XLKO mice (Figure 1B).

qRT-PCR using total RNA from femur samples (bone marrow flushed out) showed that XLαs mRNA levels were significantly lower in paternal XLKO mice than in WT or maternal XLKO littermates (Figure 1C). While this finding was consistent with the silencing of the maternal allele in bone, other comparisons did not corroborate this conclusion. No statistically significant
differences could be detected between the levels in homozygous XLKO mice and either WT or maternal XLKO (Figure 1C). Separate analysis of males and females did not reveal any significant differences between the groups, owing partly to the reduced sample sizes (Figures 1D,E).

**Intercrosses of C57BL/6 and 129/Sv Mice Allows Identification of Parental Gnas Alleles**

To determine allelic XLαs expression without relying on gene disruption, we then took advantage of a polymorphism located in Gnas exon 11, as described (Tafaj et al., 2017). The 129/Sv mice carry a cytosine (C), while C57BL/6 and CD1 strains carry a guanine (G) in the Gsα transcript (NM_201616.2, c.1009; rs13460569). We thus set up matings between 129/Sv males and C57BL/6 females and analyzed the offspring at age 14 weeks. RT-PCR using total RNA isolated from BMSCs amplified specific products from Gsα, XLαs, and A/B transcripts including the exon 11 polymorphism, and those products were then digested with BanII, a restriction enzyme that recognizes the polymorphism and differentially cleaves the paternally-derived C-containing products (Figure 2A). BanII partially cleaved the Gsα-derived products (Figure 2B), consistent with the previously demonstrated biallelic expression of this Gnas product in multiple tissues (Tafaj et al., 2017). In contrast, the A/B-derived products were completely cleaved, indicating that, consistent with previous observations (Tafaj et al., 2017), the A/B expression was nearly completely paternal (Figure 2B). A significant portion of the XLαs-derived RT-PCR products was cleaved; however, a faint band representing non-cleaved products were also visible, suggesting that XLαs expression may not be exclusively paternal in BMSCs (Figure 2B).

**NGS to Quantitate the Parental Origin of XLαs Expression**

To have a quantitative assessment of XLαs expression from paternal vs. maternal Gnas alleles, we then subjected the RT-PCR products to NGS. Providing sequence data from thousands of molecules from each PCR amplicon, this approach revealed the origin of each read with respect to its parental origin, i.e., C-containing reads are derived from the paternal allele, while G-containing reads are from the maternal allele. We analyzed BMSCs and femur, as well as cerebellum, in which XLαs was shown to be expressed at high levels (Pasolli et al., 2000). As shown in Figures 2C–E and Supplementary Table 2, the Gsα products contained ~50% C-containing products in all the tissues tested, thus confirming the biallelic transcription of Gsα. The C-containing reads in A/B transcript-derived PCR products were nearly 100% of the total in all three tissues, indicating exclusive paternal expression. In XLαs-derived RT-PCR products, however, the ratio of C-containing to G-containing reads varied significantly from sample to sample, particularly in BMSCs.

---

**FIGURE 2** The use of an exon 11 C-to-G polymorphism reveals significant sample-to-sample variation in allelic XLαs expression. (A) Schematic presentation of XLαs, A/B, and Gsα transcripts in the mouse Gnas locus. The cytosine nucleotide in SNP rs13460569 introduces a BanII restriction site. The intercrosses of C57BL/6 and 129/Sv mice were designed, such that the BanII site is present on the paternal Gnas allele (i.e., inherited from the 129/Sv fathers). The expected sizes are depicted for each RT-PCR amplicon below. (B) Agarose gel electrophoresis of BanII-digested and undigested RT-PCR amplicons, using total RNA of BMSCs from 14-week old F1 generation mice. First lane, DNA ladder. (C–E) The percentage of C-containing (paternal) NGS reads relative to the total number of reads. Complete data from females (D) and data from males (E) are shown separately from individual mice. The RT-PCR products using total RNA from BMSCs, bone, and cerebellum of 14 week-old F1 generation mice were subjected to NGS. *p < 0.05 regarding the difference between the distribution of data points for XLαs and A/B (the Wilcoxon rank-sum test).
Allele-Specific XLαs Expression

FIGURE 3 | Allele-specific XLαs expression in cultured preosteoblasts and osteoblasts is almost exclusively paternal. The mRNA levels of osteoblast markers Ibsp (A), Bglap (B), and Dmp1 (C) were measured to confirm osteoblastic differentiation of calvarial preosteoblasts. qRT-PCR was used with β-actin as reference control. *p < 0.05; ***p < 0.001 vs. non-differentiated by two-tailed Student’s t-test (n = 7). (D) Percent of C-containing (paternal) NGS reads in RT-PCR amplicons from Gsα, XLαs, and A/B transcripts in non-differentiated and 14 day-differentiated preosteoblasts. Data are from individual F1 mice of C57BL/6 × 129/Sv intercrosses.

ranging from 43.0 to 99.9% among six independent samples (Figures 2C–E and Supplementary Table 2). Modest sample-to-sample variation was also detectable in bone (83.7–99.6%) and cerebellum (83.8–100%; Figures 2C–E and Supplementary Table 2), and the variation observed in XLαs-derived products was significantly different from the variation observed in A/B-derived products in all three tissues.

Allelic XLαs Expression in Differentiated Osteoblasts

As another type of cultured primary cells, we examined mouse calvarial pre-osteoblasts from the C57BL/6-129/Sv intercrosses before and after culturing them under osteogenic conditions for 14 days. qRT-PCR experiments confirmed the osteoblast markers bone sialoprotein (Ibsp), osteocalcin (Bglap), and dentin matrix protein-1 (Dmp1) (Figures 3A–C). The NGS analysis of Gsα-derived RT-PCR products showed comparable numbers of C- and G-containing reads in both non-differentiated and differentiated cells, indicating biallelic expression (Figure 3D). In contrast, C-containing reads were nearly 100% of total reads for both XLαs and A/B products in those cells and there was no evidence of variation in the allelic XLαs expression (Figure 3D).

We then analyzed a new set of BMSCs both before and after osteogenic differentiation, which was confirmed by measuring the levels of Ibsp and Dmp1 mRNA (Figures 4A,B). In this new set of samples, while the paternal expression of A/B was nearly 100%, the paternal XLαs expression varied modestly from 80.3 to 88.5% of total (Figure 4C and Supplementary Table 3). This finding confirmed the significant contribution from the maternal allele to XLαs expression (mean = 16.1 ± 1.5%, p < 0.001 vs. the hypothetical 0% maternal). Combined, the mean maternal expression in all our BMSC samples (n = 11) was 17.6 ± 4.9% (95% confidence interval: 6.6–28.6%; p < 0.01 vs. the hypothetical value of 0%). Strikingly, when cells were grown under osteoinductive conditions for 2 weeks, the expression of XLαs shifted in the favor of the paternal allele, from 83.9 ± 1.5% paternal in non-differentiated to 97.2 ± 1.1% paternal in differentiated BMSCs (Figure 4C).

We also tested human BMSCs from two unrelated individuals, employing a C-to-T polymorphism located in GNAS exon 5 (rs7121, chr20:58903752, hg38). The samples (#231 and #236)
were cultured under osteogenic conditions before examining the relative contribution of each allele to Gsα and XLαs expression. Sanger sequencing of Gsα-derived RT-PCR products revealed that both samples were heterozygous for the polymorphism (Figure 4D). Subsequent NGS of those products showed comparable numbers of reads containing either C or T at the polymorphic site, with T-containing reads making up 50.4 or 54.0% of total reads (Figure 4E). In contrast, NGS of XLαs-derived RT-PCR products yielded 91.3 and 99.6% T-containing reads in #231 and #236, respectively (Figure 4E), indicating predominantly or nearly exclusively monoallelic expression.

**DISCUSSION**

In this study, we examined the parental contribution of GNAS allele to XLαs expression in non-clonal BMSCs and other murine tissues. In bone and cultured calvarial osteoblasts, XLαs expression was nearly exclusively paternal. In contrast, substantial maternal contribution was detected in non-differentiated BMSCs. The expression of Gsα was biallelic and that of A/B was virtually exclusively paternal in all the investigated cells/tissues.

To assess allelic XLαs expression, we first measured XLαs mRNA levels in paternal, maternal, and homozygous XLKO mice and their wildtype littermates. A similar approach has been used to measure the monoallelic expression of Gsa in certain tissues, such as proximal renal tubules (Turan et al., 2014). However, although the results appeared broadly consistent with an allelic bias of XLαs expression in bone, the mRNA levels varied widely, even within the same genotype. As this approach relied on the loss of XLαs production from the disrupted allele, this variability

---

**FIGURE 4** Allele-specific XLαs expression becomes increasingly paternal with osteoblastic differentiation of BMSCs. The mRNA levels of osteoblast markers Ibsp (A) and Dmp1 (B) were measured to confirm osteoblastic differentiation of BMSCs. qRT-PCR was used with β-actin as a reference control. **p < 0.01 vs. non-differentiated by two-tailed Student’s t-test (n = 5). (C) Percent of C-containing (paternal) NGS reads in XLαs RT-PCR amplicons before and after differentiation toward the osteoblast lineage. Data are from individual F1 intercrosses of C57BL/6 × 129/Sv. **p < 0.01 vs. non-differentiated by paired Student’s t-test. (D) Sanger sequencing traces showing the heterozygous GNAS exon 5 C-to-T polymorphism in two separate human BMSC (hBMSC) samples. (E) Percentage of T-containing reads relative to total reads obtained from the NGS of Gsa and XLαs RT-PCR products. The total number of NGS reads for each amplicon is indicated. T-containing reads for #231-Gsa: 4017 (forward), 17727 (reverse); #231-XLαs: 1179 (forward), 21533 (reverse); #236-Gsa: 6522 (forward), 33294 (reverse); #236-XLαs: 922 (forward), and 20448 (reverse).
may reflect some detectable levels of XLαs mRNA being made from the latter allele, in addition to the outbred CD1 background in which XLKO mice had to be maintained (Plagge et al., 2004).

As an alternative approach, we utilized a known polymorphism in the mouse Gnas locus. We subjected the RT-PCR products to NGS, since it has been utilized for quantitatively detecting mosaic single nucleotide variants in clinical settings (Narumi et al., 2013). Indeed, NGS allowed us to obtain sequence information from thousands of reads and distinguish the allelic origin of the products. We analyzed the allele-specific XLαs and Gsα expression in human BMSCs similarly, using NGS and a common polymorphism (Campbell et al., 1994). In the human samples, genotypes of the donors’ parents were unknown. Therefore, although we could quantify the allele-specific expression, we were unable to determine the parental origin.

Michienzi et al. examined clonal BMSCs from wildtype and fibrous dysplasia-derived samples and showed evidence of biallelic XLαs expression, as well as parental Gsα expression that appeared asymmetrical (Michienzi et al., 2007). We analyzed non-clonal BMSCs passaged no more than three times. In total, we found biallelic XLαs expression in one sample and substantial deviation from monoallelic expression in seven samples, while the results from the remaining three samples were consistent with nearly exclusive paternal expression. There might be an influence of cell culture on our results. Nonetheless, no such variation was observed among our calvarial osteoblast samples, which were also cultured. Moreover, in BMSCs that were differentiated in culture toward the osteoblast lineage, the XLαs expression became more significantly paternal, arguing against the possibility that culture conditions caused a relaxation of XLαs imprinting.

A plausible explanation for the observed variation in allelic XLαs expression in our BMSC samples may be cellular heterogeneity, as BMSCs are known to be heterogeneous with variable representations of cell types in different samples (Kfoury and Scadden, 2015). Therefore, it is likely that XLαs is expressed biallelically in a certain subset of cells in the bone marrow, as well as in some other tissues. Regarding the study by Michienzi et al. (2007), the analyzed clonogenic BMSCs may have been derived from the cell-type(s) in which XLαs expression is biallelic. Alternatively, the maternal XLαs promoter may be active in all cell types in the BMSC samples but at a lower level than the paternal XLαs promoter. However, when considering the heterogeneity of BMSCs regarding cell types and the variation we observed among the samples, the former possibility appears more plausible. The finding that substantial XLαs expression occurs from the maternal allele in certain cell types has important implications. The physiological roles of XLαs in vivo have thus far been deduced from findings in mice or patients in whom the paternal XLαs allele is disrupted alone, assuming a complete loss of this protein in all tissues. According to our results, some of those interpretations could be at least partially incorrect.

We found paternal XLαs expression in mouse whole bones, although significant but modest sample-to-sample variation was observed in the paternal contribution, as opposed to A/B expression, which appeared consistently ~100% paternal. XLαs is substantially expressed in the cerebellum (Pasolli et al., 2000). We also detected mild variation in the allelic expression of XLαs among our mouse cerebellum samples, suggesting that in both bone and cerebellum, there may be a small subset of cells in which XLαs expression is biallelic.

Unlike the allelic expression data, we did not detect differences in DNA methylation between non-differentiated and differentiated BMSCs. The data for the methylation analysis reflected all the cells in the sample while the expression data originated only from cells that express XLαs. Since the methylation differences are expected to occur only in XLαs-expressing cells, they may have remained under our detection limit, particularly if those cells are scarce. Alternatively, other methylated regions or regulatory events may dictate the allelic shift of XLαs expression during osteogenic differentiation. The analyzed XLαs promoter region lies within a germline imprint including the Gnas antisense exon 1 (also known as Nespas; Coombes et al., 2003; see Figure 5A). It is possible that a different part of this germline imprint regulates the XLαs promoter.
activity. Also, a methylation-independent mechanism may be involved, considering that an “uncoupling” of allelic silencing and promoter DNA methylation has been described for the Nespas-mediated regulation of the Nesp55 promoter activity (Williamson et al., 2011). The regulation of allelic expression in this locus is certainly complex. It is also worth mentioning that the analyzed XLαs promoter region is orthologous to human GNAS-AS2, a region shown to be severely hypomethylated (i.e., loss of methylation) in patients with both sporadic and familial pseudohypoparathyroidism type-Ib (MIM: 603233) (Rochtus et al., 2016). Whether the hypomethylation is associated with biallelic XLαs expression is unknown.

Tissue- or cell type-specificity has been shown for the monoallelic expression of some transcripts, including Gsα, which is biallelic in most but predominantly maternal in some tissues (Yu et al., 1998). Conversely, Dlk1, a product of the imprinted gene cluster on chromosome 14, is paternally expressed nearly in all tissues but exhibits biallelic expression in postnatal neural stem cells and niche astrocytes (Ferron et al., 2011). Our observations regarding the allelic expression of XLαs are analogous to those documented for Dlk1 and supports the likelihood that XLαs is expressed biallelically in certain cell types. Identification of those cells may reveal important novel roles of XLαs.

In summary, our findings indicate that the maternal GNAS allele contributes significantly to XLαs expression in BMSCs. Thus, altered XLαs actions could be involved in at least some of the phenotypes associated with GNAS mutations even if the mutation is maternal.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Boston University School of Medicine Institutional Research Board. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Subcommittee on Research Animal Care, Massachusetts General Hospital. Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

QC: investigation, methodology, formal analysis, visualization, writing, and original draft. CA, BA, CR, MG, and MD: investigation. AP and LG: resources, writing—review, and editing. QH: investigation, methodology, writing—review, and editing. MB: conceptualization, formal analysis, funding acquisition, supervision, visualization, writing—original draft. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded in part by a research grant from the United States. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073911 to MB). The statistical analyses were conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL 1TR002541) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.

ACKNOWLEDGMENTS

We thank Gavin Kelsey (Babraham Institute, Cambridge, United Kingdom) for kindly providing the XLKO mice.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.680537/full#supplementary-material

REFERENCES

Afgan, E., Baker, D., Batut, B., van den Beek, M., Bouvier, D., Cech, M., et al. (2018). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 46, W537–W544.

Aldred, M. A., Aftimos, S., Hall, C., Waters, K. S., Thakker, R. V., Trembath, R. C., et al. (2002). Constitutional deletion of chromosome 20q in two patients affected with Albright hereditary osteodystrophy. Am. J. Med. Genet. 113, 167–172. doi: 10.1002/ajmg.10751

Aydin, C., Aytan, N., Mahon, M. J., TawfEEK, H. A., Kowall, N. W., Dedegolu, A., et al. (2009). Extralarge XLαs (XXLαs), a variant of stimulatory G protein alpha-subunit (Gsα), is a distinct, membrane-anchored GNAS product that can mimic Gsα. Endocrinology 150, 3567–3575. doi: 10.1210/en.2009-0318

Bastpe, M. (2007). The GNAS locus: quintessential complex gene encoding galpha, XLalphas, and other imprinted transcripts. Curr. Genomics 8, 398–414. doi: 10.2174/1389202707783406488

Bastpe, M., Gunes, Y., Perez-Villamil, B., Hunzelman, J., Weinstein, L. S., and Jüppner, H. (2002). Receptor-mediated adenylyl cyclase activation through XLalphas, the extra-large variant of the stimulatory G Protein alpha-subunit. Mol. Endocrinol. 16, 1912–1919. doi: 10.1210/me.2002-0054

Campbell, R., Gosden, C. M., and Bontrhron, D. T. (1994). Parental origin of transcription from the human GNAS1 gene. J. Med. Genet. 31, 607–614. doi: 10.1136/jmg.31.6.607

Chen, X., Meng, Y., Tang, M., Wang, Y., Xie, Y., Wan, S., et al. (2020). A paternally inherited non-sense variant c.424G>T (p.G142W) in the first exon of XLalphas in an adult patient with hypophosphatemia and osteopetrosis. Clin. Genet. 97, 712–722. doi: 10.1111/cge.13734
Michienzi, S., Cherman, N., Holmbeck, K., Funari, A., Collins, M. T., Bianco, P., He, Q., Bouley, R., Liu, Z., Wein, M. N., Zhu, Y., Spatz, J. M., et al. (2017). GDH3 transcript in skeletal progenitors: evidence for random asymmetric allelic expression of Gsα. J. Biol. Chem. 292, 177–187. doi: 10.1074/jbc.M116.764023

Klemke, M., Pasolli, H. A., Kehlenbach, R. H., Wang, Y., and Huttner, W. B. (2000). The large G protein alpha-subunit XLαs limits clathrin-mediated endocytosis and regulates tissue iron levels in vivo. J. Biol. Chem. 275, 33633–33640. doi: 10.1074/jbc.M002654200

Yu, S., Yu, D., Lee, E., Eckhaus, M., Lee, R., Corria, Z., et al. (1998). Potent constitutive cyclic AMP-generating activity of XLalphas. II. Signal transduction properties. J. Biol. Chem. 273, 36563–36569. doi: 10.1074/jbc.273.50.36563

Plagge, A., Gordon, E., Dean, W., Boiani, R., Cinti, S., Peters, J, et al. (2004). The imprinted signaling protein XLalphas is required for postnatal adaptation to feeding. Nature Genet. 36, 818–826. doi: 10.1038/ng1397

Plagge, A., Kelsey, G., and Germain-Lee, E. L. (2008). Physiological functions of the imprinted Gnas locus and its protein variants Galphas(β) and XLalphas(β) in human and mouse. J. Endocrinol. 196, 193–214. doi: 10.1677/joe-07-0444

Richard, N., Molin, A., CourdRAY, N., Rault-Guillaume, P., Juppner, H., and Kottler, M. L. (2013). Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLalphas in fetal development. J. Clin. Endocrinol. Metab. 98, E1549–E1556.